https://www.selleckchem.com/pr....oducts/lonafarnib-sc
This approach provides novel insights into prognostic stratification of HGSOC patients and may contribute to personalized treatment strategies in the future.The vast majority (90%) of glioblastoma (GBM) patients belong to the isocitrate dehydrogenase 1 wild type (IDH1WT) group which exhibits a poor prognosis with a median survival of less than 15 months. This study demonstrated numerous immunosuppressive genes as well as β-catenin gene, pivotal for Wnt/β-catenin signaling, were upregulated in 206 IDH1WT glioma patients u
Like
Comment
Share
